To include your compound in the COVID-19 Resource Center, submit it here.

CytRx, Orphazyme deal

Orphazyme said the technology complements its development of heat shock protein-based therapies for lysosomal storage diseases, including lead

Read the full 185 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE